A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer

Eur J Surg Oncol. 2005 Nov;31(9):1006-10. doi: 10.1016/j.ejso.2005.05.009. Epub 2005 Jul 7.

Abstract

Aims: To provide a large database of pre-operative CA 125 levels which may predict inappropriate cytoreductive surgery in patients with advanced epithelial ovarian cancer.

Methods: A multicenter review of the records of 424 patients with FIGO stage III and IV epithelial ovarian cancer of patients who underwent primary cytoreductive surgery was performed. The validity of pre-operative CA 125 level measurement as a single predictor of the possibility to achieve only suboptimal cytoreduction was evaluated by calculating the sensitivity and the specificity of various cut-off values. The relative importance of different cut-off values in achieving the best predictive validity was assessed by a receiver operating characteristics (ROC) curve.

Results: Optimal cytoreduction (largest diameter of residual tumour < or =1 cm) was achieved in 242 patients. The median CA 125 level in optimally cytoreduced patients was lower than in those patients suboptimally debulked (304 vs 863 U/mL; p<0.001). The area under the ROC curve was 0.65 (95% confidence interval, 0.60-0.71) and the CA 125 threshold derived from the ROC was 400 U/mL. The accuracy of the test at this level was 62%.

Conclusions: The clinical applicability of the ROC derived CA 125 threshold is limited. The data accrued in the study provides a basis for decision-making regarding the place of primary surgery various CA 125 levels.

Publication types

  • Multicenter Study

MeSH terms

  • Biomarkers, Tumor / analysis
  • CA-125 Antigen / analysis*
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery*
  • Predictive Value of Tests
  • ROC Curve
  • Sensitivity and Specificity
  • Unnecessary Procedures

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen